OptaBlate Procedure: Candidates & Recovery | Dr. Amit Sharma
“My MRI shows Modic changes. Is OptaBlate appropriate for me, and how is it different from Intracept?”
OptaBlate is a newer device platform for basivertebral nerve ablation. It treats the same anatomical pain pathway as Intracept, but device clearance does not mean that every patient with Modic changes is a candidate or that one platform has been proven clinically superior.
OptaBlate is an FDA-cleared system used to perform basivertebral nerve ablation for carefully selected patients with chronic vertebrogenic low back pain. The procedure targets the basivertebral nerve inside selected vertebral bodies from L3 through S1.
This is the device-specific companion to the broader Basivertebral Nerve Ablation guide. The parent guide explains the diagnosis and treatment category; this page focuses on the OptaBlate platform, candidacy, procedure, recovery and evidence limitations.
The Quick Answer
- OptaBlate is a device platform for basivertebral nerve ablation.
- It received FDA 510(k) clearance on May 15, 2025.
- Its FDA-cleared indication concerns chronic low back pain lasting at least six months, failure of at least six months of conservative care and Modic Type 1 or Type 2 changes from L3 through S1.
- Modic changes are necessary imaging evidence but are not sufficient by themselves.
- The procedure is minimally invasive, implant-free and generally performed on an outpatient basis.
- OptaBlate and Intracept target the same nerve but use different instruments and RF protocols.
- No published head-to-head trial has established better patient outcomes with one platform.
- Most long-term BVN-ablation evidence was generated using Intracept, not OptaBlate.
What Is the OptaBlate Procedure?
The OptaBlate BVN Intraosseous Nerve Ablation System is a Class II medical device used to create a controlled thermal lesion at the basivertebral nerve. This sensory nerve lies inside the vertebral body and can carry pain signals from damaged vertebral endplates.
During the procedure, the physician uses fluoroscopic guidance to enter the targeted vertebral body through the pedicle. A controlled path is created toward the basivertebral nerve, and the OptaBlate probe delivers radiofrequency energy at the planned location.
The treatment does not remove a disc, repair an endplate, decompress a spinal nerve, fuse the spine or leave a permanent implant. It interrupts a specific sensory pathway associated with vertebrogenic pain.
When Did OptaBlate Receive FDA Clearance?
The FDA issued 510(k) clearance for the OptaBlate BVN system on May 15, 2025. The system was cleared through a substantial-equivalence pathway using the Intracept Intraosseous Nerve Ablation System as the predicate device.
FDA-cleared is the accurate description.
A 510(k) clearance establishes substantial equivalence to a legally marketed predicate device. It is not the same process as approval of a new drug, and it does not prove that OptaBlate produces better clinical outcomes than Intracept.
What Type of Back Pain Does OptaBlate Treat?
OptaBlate is intended for vertebrogenic low back pain. This pain is thought to arise from damaged vertebral endplates and adjacent vertebral marrow, with signals traveling through the basivertebral nerve.
The clinical pattern is usually predominantly axial rather than leg-dominant. Patients may describe deep central lower-back pain aggravated by sitting, bending forward, lifting or moving from sitting to standing. This pattern can overlap with discogenic, facet, sacroiliac and muscular pain, so symptoms alone are not diagnostic.
What Do Modic Type 1 and Type 2 Changes Mean?
Modic changes are MRI findings adjacent to a vertebral endplate:
- Modic Type 1: marrow changes commonly associated with edema and inflammation.
- Modic Type 2: fatty replacement within the vertebral marrow adjacent to the endplate.
The FDA-cleared indication for OptaBlate includes features consistent with Modic Type 1 or Type 2 changes from L3 through S1. Modic changes support the diagnosis, but they do not prove that the endplate is the dominant pain generator.
Who May Be a Candidate for OptaBlate?
A potential OptaBlate candidate generally has a combination of symptoms, MRI findings and treatment history. One abnormal MRI phrase is not enough.
Features That Support Candidacy
- Predominantly axial lower-back pain
- Pain lasting at least six months
- Inadequate improvement after at least six months of appropriate conservative care
- Modic Type 1 or Type 2 changes at one or more levels from L3 through S1
- Symptoms and MRI findings that correspond anatomically
- No untreated diagnosis that better explains the dominant symptoms
- A medical and anatomical profile that permits safe transpedicular access
Are Modic Changes Enough to Qualify?
No. Many patients have more than one potential source of low back pain. The actual MRI images should be reviewed alongside the pain pattern, examination, prior treatment responses and competing diagnoses.
| More Consistent With Vertebrogenic Pain | Suggests Another or Additional Generator |
|---|---|
| Deep, central axial low back pain | Dominant electric or shooting pain below the knee |
| Pain worsened by sitting, bending or lifting | Progressive weakness or dermatomal sensory loss |
| Matching Modic Type 1 or Type 2 endplate changes | Neurogenic claudication from significant spinal stenosis |
| Persistent symptoms despite appropriate nonsurgical care | Strongly confirmed facet or sacroiliac-joint pain |
| No alternative diagnosis better explains the symptoms | Fracture, infection, tumor or substantial instability |
When OptaBlate May Not Be the Right Treatment
OptaBlate is not a general treatment for every abnormal lumbar MRI or every form of chronic low back pain. It does not directly treat pain caused primarily by:
- Facet-joint pain
- Sacroiliac-joint pain
- Classic radiculopathy or sciatica from nerve-root compression
- Neurogenic claudication from lumbar spinal stenosis
- Symptomatic instability or high-grade spondylolisthesis
- Acute or unhealed vertebral compression fracture
- Active infection, tumor or another destructive vertebral process
- Predominantly myofascial pain
- Hip disease or another nonspinal condition
Some patients have mixed pain. A successful BVN procedure may improve the vertebrogenic component without eliminating pain from another structure.
How Does the OptaBlate Procedure Work?
The procedure is performed under fluoroscopic guidance. The physician advances an access cannula through the pedicle, creates a controlled curved path inside the vertebral body and positions the bipolar RF probe at the planned basivertebral nerve target. Radiofrequency energy then creates a thermal lesion intended to interrupt pain transmission through the nerve.
The OptaBlate Procedure Pathway
Symptoms, actual MRI images and competing pain generators are reviewed.
The physician advances a cannula through the pedicle under fluoroscopic guidance.
A curved access path allows the RF probe to reach the planned BVN target.
Controlled RF energy creates the planned thermal treatment zone.
The patient is monitored, discharged and followed as soreness settles and function changes.
What Is Different About the OptaBlate System?
According to Stryker and the FDA clearance summary, device characteristics include:
- A bipolar radiofrequency probe
- A steerable curved introducer for target positioning
- A Microinfuser that delivers saline to help manage tissue impedance
- A 10-gauge access system
- A manufacturer-specified 95°C, seven-minute RF protocol
- A manufacturer-reported treatment zone of at least 1 cm under specified test conditions
- Multiple generator channels that can support simultaneous ablations when clinically appropriate
Technical features are not the same as proven clinical superiority.
A faster RF cycle, different probe or larger manufacturer-tested lesion does not by itself prove better pain relief, better function or fewer complications. Those outcomes require comparative clinical evidence.
Anesthesia, Procedure Time and Discharge
Many basivertebral nerve ablation procedures are performed under general anesthesia. Selected patients may instead undergo the procedure with monitored anesthesia care, or MAC sedation. The choice is individualized according to medical status, airway considerations, tolerance of prone positioning, anatomy, treatment duration, number of vertebral bodies and the anesthesiology team’s judgment.
Most patients are discharged the same day and require a responsible adult to drive them home. Follow the facility’s instructions concerning fasting, medication, driving and activity.
Can OptaBlate Be Performed Under MAC Sedation?
Yes, in selected patients. Dr. Sharma has performed basivertebral nerve ablation under MAC sedation for more than two years. Avoiding general anesthesia may be valuable for some patients because it can avoid airway instrumentation and certain general-anesthesia considerations. However, MAC is still anesthesia care, has its own risks and is not automatically safer or appropriate for every patient. The anesthesia team must remain prepared to deepen or convert the anesthetic if clinically necessary.
In Dr. Sharma’s experience, anesthesia teams often prefer to limit a MAC-sedation session to approximately three treated vertebral bodies. This matters because three adjacent painful disc-endplate complexes may require treatment of four vertebral bodies. For example, disease involving L3-4, L4-5 and L5-S1 may require BVN ablation at L3, L4, L5 and S1.
| Clinical Situation | Possible Practice Approach |
|---|---|
| One to three vertebral bodies treated under MAC | May be completed in one session when the patient and anesthesia plan are appropriate |
| Four vertebral bodies required using a longer workflow | May be divided into two staged visits to remain within the agreed MAC duration |
| Four vertebral bodies treated with OptaBlate | May sometimes be completed in one MAC session when the shorter workflow, patient factors and anesthesia team permit |
Dr. Sharma has found the OptaBlate workflow somewhat shorter and less mechanically demanding in his own practice. That has sometimes allowed treatment of all four required vertebral bodies during one MAC-sedation visit rather than two staged visits.
This is a practice observation, not comparative proof.
No head-to-head clinical trial has established that OptaBlate is less traumatic, safer under MAC or appropriate for more levels in one session. The decision to use MAC, general anesthesia or staged treatment remains individualized and must be agreed upon by the procedural and anesthesia teams.
Preparing for the OptaBlate Procedure
The treating team should review anticoagulants, antiplatelet medication, diabetes, infection symptoms, allergies, pregnancy status, implanted electronic devices and the anesthesia plan before the procedure.
Do not stop aspirin, warfarin or another blood thinner independently.
Any interruption must be coordinated with the prescribing clinician and procedural physician. The risk of bleeding must be balanced against the risk of stopping the medication.
Fasting and medication instructions depend on the anesthesia plan. The individualized instructions from the treating facility supersede general online information. Review the practice guide to planning for a procedure.
OptaBlate Recovery Time
OptaBlate is usually outpatient, but access through the pedicle and treatment inside the vertebral body can produce genuine postoperative soreness. Recovery instructions should be individualized rather than reduced to a universal promise.
| Time After OptaBlate | What Patients May Experience | General Interpretation |
|---|---|---|
| Procedure day | Monitoring after anesthesia, incision soreness and deeper aching near treated levels | A driver is required; follow discharge instructions |
| First several days | Local tenderness, muscle soreness or temporary increase in back pain | Early soreness does not determine the final result |
| One to two weeks | Many patients progressively resume ordinary daily activities | Work and lifting depend on symptoms and job demands |
| Several weeks | Some patients begin noticing improvement in familiar axial pain and function | Assess activity tolerance as well as pain score |
| Two to three months | Improvement may continue developing as activity and conditioning progress | A more useful interval for judging the overall response |
How Long Does OptaBlate Take to Work?
Improvement after basivertebral nerve ablation may develop gradually over several weeks and can continue over two to three months. Immediate relief is not required, and early procedural soreness should not be mistaken for treatment failure.
Meaningful outcome measures include improvement in the patient’s familiar central back pain, sitting and standing tolerance, bending, lifting, sleep, work capacity and ability to participate in rehabilitation.
When Should You Contact the Treating Team?
Contact the treating team promptly for severe or rapidly escalating pain, fever, chills, drainage, increasing redness or swelling, new weakness, spreading numbness, loss of balance, bowel or bladder dysfunction, saddle-region numbness or another symptom that differs substantially from the expected recovery instructions.
What Evidence Supports OptaBlate?
The evidence must be separated into two categories:
- Device evidence: The FDA clearance summary documents OptaBlate’s engineering, performance testing and substantial equivalence to Intracept.
- Clinical outcome evidence: Randomized trials and five-year follow-up support basivertebral nerve ablation in carefully selected patients, but those pivotal studies primarily evaluated the Intracept system.
As of August 2026, a published head-to-head clinical trial has not established that OptaBlate provides better pain relief, function, durability or safety than Intracept. A prospective observational study of outcomes using the OptaBlate system is registered, but its results are not yet available.
What FDA substantial equivalence does and does not mean
The FDA concluded that OptaBlate has the same intended use and similar indications and technological characteristics as its predicate. That supports legal marketing of the device; it is not a randomized comparison of patient outcomes.
OptaBlate vs Intracept: What Should Patients Know?
Both systems perform basivertebral nerve ablation and target the same anatomical pain pathway. Their FDA-cleared indications are similar. The platforms differ in access instruments, probe design, RF temperature and duration, and impedance-management strategy.
The practical device choice should consider physician experience, target geometry, anatomy, equipment availability and informed discussion of the evidence. It should not be based solely on a manufacturer’s claim about lesion size or treatment speed.
For the full technical and evidence comparison, read OptaBlate vs Intracept: Two Devices, One Nerve, No Head-to-Head Data. For the established Intracept patient pathway, see the Intracept procedure guide.
OptaBlate Risks and Limitations
Potential risks include:
- Temporary incision or procedural soreness
- Temporary increase in back pain
- Bleeding or hematoma
- Infection
- Allergic or medication reaction
- Transient numbness, tingling or weakness
- Injury to a nearby neural or vascular structure
- Pedicle or vertebral injury
- Incomplete, temporary or absent relief
- Anesthesia-related complications
- Need to evaluate or treat another pain generator
Contraindications and precautions depend on current device labeling, anatomy, infection status, pregnancy status, skeletal maturity, medical fitness, proximity to sensitive structures and implanted electronic devices. Final eligibility requires review of the current instructions for use and an individualized medical assessment.
OptaBlate does not repair the endplate, reverse disc degeneration, decompress a spinal nerve, correct instability or guarantee permanent pain relief. A technically successful procedure cannot compensate for an incorrect diagnosis.
Alternatives to OptaBlate
The appropriate alternative depends on the actual pain generator and patient goals. Options may include:
- Diagnosis-specific physical therapy and graded conditioning
- Medication appropriate to the suspected pain mechanism
- The Intracept system or another suitable BVN-ablation platform
- Facet medial branch blocks and facet radiofrequency ablation for confirmed facet-mediated pain
- Epidural treatment for selected radicular inflammation
- Sacroiliac-joint evaluation and treatment
- Minimally invasive decompression for qualifying spinal stenosis
- Endoscopic or conventional surgery when compression, instability or another structural indication requires correction
- Continued observation when clinically safe and symptoms remain manageable
Failure of several prior treatments does not automatically establish vertebrogenic pain. The diagnostic match remains more important than the number of treatments already attempted.
Frequently Asked Questions About OptaBlate
What is the OptaBlate procedure?
OptaBlate is an FDA-cleared system used to perform basivertebral nerve ablation. The physician accesses a selected lumbar vertebral body and uses radiofrequency energy to ablate the basivertebral nerve, which can carry pain signals from damaged vertebral endplates.
Who may qualify for OptaBlate?
A potential candidate generally has predominantly axial low back pain lasting at least six months, inadequate improvement after at least six months of conservative care and Modic Type 1 or Type 2 changes from L3 through S1 that correspond to the clinical pain pattern. Other dominant pain generators must be considered.
Are Modic changes enough to qualify for OptaBlate?
No. Modic Type 1 or Type 2 changes support the diagnosis of vertebrogenic pain, but MRI findings alone do not prove that the vertebral endplates are the dominant pain generator. Symptoms, examination, treatment history and competing diagnoses must also fit.
Is OptaBlate FDA approved?
The OptaBlate BVN Intraosseous Nerve Ablation System received FDA 510(k) clearance on May 15, 2025. FDA-cleared is the accurate regulatory description.
Is OptaBlate the same as Intracept?
No. OptaBlate and Intracept are different device platforms used to perform the same treatment category: basivertebral nerve ablation. They share the same anatomical target and similar FDA-cleared indications, but their instruments and radiofrequency protocols differ.
Has OptaBlate been proven better than Intracept?
No published head-to-head clinical trial has established that OptaBlate produces better pain or functional outcomes than Intracept. OptaBlate received FDA clearance through substantial equivalence to Intracept, while most long-term basivertebral nerve ablation outcome data were generated using Intracept.
How long is recovery after OptaBlate?
Most patients are discharged the same day. Temporary incision soreness or deeper aching may occur, and activity is advanced according to the treating physician’s instructions. Return to work depends on soreness, job demands and the number of vertebral bodies treated.
Can OptaBlate be performed under MAC sedation instead of general anesthesia?
Yes, selected patients may undergo OptaBlate with monitored anesthesia care, or MAC, rather than general anesthesia. Dr. Sharma has performed basivertebral nerve ablation under MAC sedation for more than two years. The final anesthesia plan depends on medical status, airway considerations, prone positioning, treatment duration, number of vertebral bodies and the anesthesiology team’s judgment.
How long does OptaBlate take to work?
Improvement after basivertebral nerve ablation may develop gradually over several weeks and can continue over two to three months. Early procedural soreness should not be used to judge the final response.
Does OptaBlate treat sciatica or spinal stenosis?
OptaBlate does not decompress a spinal nerve or enlarge a narrowed spinal canal. It is not designed to treat classic radicular sciatica, progressive neurological loss or neurogenic claudication caused by spinal stenosis.
Does insurance cover OptaBlate?
Coverage varies by insurer, benefit plan and applicable policy. Authorization commonly requires documentation of chronic axial low back pain, failed conservative treatment, qualifying Modic Type 1 or Type 2 changes and exclusion of another dominant pain generator.
Related OptaBlate and Vertebrogenic Pain Resources
- Basivertebral Nerve Ablation: Parent Guide
- Vertebrogenic Pain
- Intracept Procedure
- OptaBlate vs Intracept
- Discogenic Pain
- Degenerative Disc Disease
- Diagnosing Back Pain
- Preparing for a Procedure
Dr. Amit Sharma & our minimally invasive pain & spine team.
References
- U.S. Food and Drug Administration. 510(k) Premarket Notification K250213: OptaBlate BVN Intraosseous Nerve Ablation System. Decision date May 15, 2025. Read source →
- U.S. Food and Drug Administration. K250213 510(k) Summary: indications, device description and substantial-equivalence comparison. Read source →
- Stryker. OptaBlate Basivertebral Nerve Ablation System: Product and Procedure Information. Read source →
- Stryker. FDA Clearance Announcement for the OptaBlate BVN System. May 19, 2025. Read source →
- Sayed D, Naidu RK, Patel KV, et al. Best Practice Guidelines on the Diagnosis and Treatment of Vertebrogenic Pain With Basivertebral Nerve Ablation From the American Society of Pain and Neuroscience. Journal of Pain Research. 2022;15:2801-2819. Read source →
- Fischgrund JS, Rhyne A, Macadaeg K, et al. Long-Term Outcomes Following Intraosseous Basivertebral Nerve Ablation for the Treatment of Chronic Low Back Pain: Five-Year Treatment Arm Results. European Spine Journal. 2020;29(8):1925-1934. Read source →
- Khalil JG, Truumees E, Macadaeg K, et al. Intraosseous Basivertebral Nerve Ablation: A Five-Year Pooled Analysis From Three Prospective Clinical Trials. Interventional Pain Medicine. 2024;3(4):100529. Read source →
- Centers for Medicare & Medicaid Services. Local Coverage Determination L39644: Intraosseous Basivertebral Nerve Ablation. Coverage depends on the applicable contractor and current policy. Read source →
- ClinicalTrials.gov. Prospective Cohort Study of Outcomes Following Treatment With the Stryker OptaBlate BVN System. Read study record →
- American Society of Anesthesiologists. Statement on Distinguishing Monitored Anesthesia Care From Moderate Sedation/Analgesia. Read source →
About the Author
Amit Sharma, MD is an interventional spine and pain-management physician who performs basivertebral nerve ablation and other image-guided, endoscopic and minimally invasive spine procedures. He has clinical experience with both the OptaBlate and Intracept platforms.
Medical disclaimer: This page is educational and does not replace individualized medical evaluation, diagnosis or treatment. OptaBlate is not appropriate for every patient with chronic low back pain or Modic changes. Candidacy, preparation, anesthesia, risks, recovery instructions, device selection and insurance coverage vary according to anatomy, medical history, diagnosis, facility requirements, current device labeling and coverage policies. Seek urgent medical attention for new weakness, bowel or bladder dysfunction, saddle-region numbness, fever with worsening spinal pain or rapidly progressive neurological changes.
Last medically reviewed: August 2026
